Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 3 | 4 | 3 | 5 | 3 | 2 | 4 | 3 | 5 |
Altman Z-Score |
— | 36.84 | 27.96 | 5.20 | 12.03 | 1.44 | 0.19 | (1.45) | (1.47) | 0.84 |
P/S ratio |
1.79 | 83.01 | 59.07 | 18.32 | 4.71 | 10.06 | 53.33 | 22.71 | 2.75 | 3.96 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.40 |
Altman Z″-Score (non-manufacturers) |
4.13 | 18.15 | 26.06 | 15.85 | 24.50 | 4.57 | 1.64 | (1.26) | (1.29) | (0.30) |
P/Operating CF |
(5.36) | (275.76) | (85.38) | (18.54) | 10.41 | (25.12) | (51.35) | (11.34) | (3.76) | 9.48 |
Beneish M-Score |
1.11 | (2.33) | (4.21) | — | — | — | 3.11 | (1.09) | 1.51 | (2.34) |
P/B ratio |
0.00 | 4.31 | 2.16 | 0.72 | 0.99 | 1.78 | 2.09 | 4.42 | 3.54 | 24.98 |
Price to Tangible BV |
0.00 | 4.31 | 2.16 | 0.72 | 0.99 | 1.78 | 2.09 | 4.42 | 3.54 | 24.98 |
EV/Sales |
(0.45) | 67.94 | 35.16 | (4.92) | 0.00 | 1.42 | 10.68 | 0.06 | (1.45) | 2.64 |
EV/EBITDA |
2.69 | 0.00 | 0.00 | 0.72 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08 | 13.61 |
EV/Operating CF |
0.84 | (55.85) | (12.88) | 1.13 | 0.00 | (1.96) | (1.49) | (0.01) | 0.98 | 31.49 |
EV/FCF |
0.83 | (55.02) | (12.60) | 1.12 | 0.00 | (1.90) | (1.49) | (0.01) | 0.98 | 31.63 |
Quick Ratio |
9.91 | 17.74 | 19.57 | 12.67 | 19.86 | 34.10 | 16.99 | 10.62 | 9.38 | 8.94 |
Current Ratio |
10.20 | 17.93 | 19.89 | 12.79 | 20.01 | 34.40 | 17.16 | 10.87 | 9.51 | 9.07 |
Net Debt/EBITDA |
13.40 | 8.42 | 6.31 | 3.44 | 18.06 | 10.11 | 3.83 | 2.27 | 3.14 | (6.84) |
Debt/Assets |
22.21% | 2.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.35 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.28 | 0.05 | 0.01 | 0.02 | 0.18 | 0.12 | 0.02 | 0.03 | 0.20 | 0.55 |
Operating CF/Net income |
2.12 | 0.65 | 0.79 | 0.71 | 0.71 | 0.79 | 0.57 | 0.74 | 0.93 | (1.49) |
Capex/Depreciation |
(0.21) | (1.58) | 1.16 | 0.66 | (0.27) | (0.52) | 2.08 | 0.10 | 0.05 | 0.04 |
Interest Coverage |
(6.60) | (16.21) | (40.39) | (103.20) | (6.03) | (131.82) | (15.25) | (9.09) | (2.29) | 0.60 |
| 11.60% | (22.33%) | (15.53%) | (21.84%) | (4.97%) | (15.35%) | (41.62%) | (93.44%) | (182.71%) | (24.49%) | |
| (7.19%) | (15.36%) | (14.71%) | (20.62%) | (4.68%) | (10.91%) | (20.54%) | (30.79%) | (31.02%) | (3.12%) | |
ROIC |
(102.47%) | (26.96%) | (70.34%) | (218.14%) | (484.87%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(8.04%) | (12.57%) | (14.90%) | (27.82%) | (5.27%) | (10.70%) | (30.41%) | (44.04%) | (37.40%) | (4.23%) |
Average Days of Receivables |
116.89 | 58.44 | 12.70 | 0.00 | 0.00 | 5.06 | 50.35 | 145.75 | 163.01 | 52.66 |
Research and Development Expense of Revenue |
92.42% | 294.43% | 1,123.92% | 1,241.73% | 106.70% | 155.91% | 863.21% | 771.01% | 179.49% | 57.96% |
Selling, General and Administrative Expense of Revenue |
25.71% | 93.38% | 310.52% | 201.18% | 25.14% | 34.02% | 356.21% | 244.48% | 46.44% | 21.63% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.95% | 43.78% | 199.22% | 155.14% | 15.33% | 24.29% | 265.93% | 193.54% | 37.30% | 15.38% |
Graham Net Nets |
1.18 | 0.17 | 0.39 | 1.19 | 0.96 | 0.42 | 0.18 | 0.11 | 0.08 | 0.02 |
Graham Number |
22.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(14.26%) | (2.43%) | (5.88%) | (33.33%) | (5.09%) | (9.04%) | (23.46%) | (42.02%) | (59.00%) | (0.90%) |
Free Cash Flow Yield |
(30.39%) | (1.49%) | (4.72%) | (24.00%) | (3.76%) | (7.44%) | (13.48%) | (31.21%) | (54.15%) | 2.11% |
Revenue per Share |
6.33 | 0.51 | 0.20 | 0.30 | 2.75 | 2.30 | 0.37 | 0.64 | 3.22 | 8.16 |
Operating CF per Share |
(3.42) | (0.98) | (1.97) | (2.57) | (0.52) | (1.67) | (2.61) | (4.49) | (4.77) | 0.68 |
Capex per Share |
(0.02) | (0.01) | (0.04) | (0.03) | (0.02) | (0.05) | (0.01) | (0.03) | (0.01) | 0.00 |
Free Cash Flow per Share |
(3.44) | (1.00) | (2.01) | (2.60) | (0.54) | (1.72) | (2.63) | (4.52) | (4.78) | 0.68 |
Cash per Share |
19.43 | 12.56 | 17.31 | 13.83 | 14.42 | 19.98 | 15.67 | 14.52 | 13.58 | 10.84 |
Shareholders Equity per Share |
14.89 | 15.55 | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | 3.27 | 2.50 | 1.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.89 | 15.55 | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | 3.27 | 2.50 | 1.29 |
Free Cash Flow |
(9.08) | (19.73) | (49.57) | (70.32) | (14.73) | (47.27) | (73.95) | (121.61) | (135.69) | 19.61 |
Working Capital |
52.50 | 238.61 | 412.38 | 348.20 | 376.74 | 537.78 | 421.15 | 369.39 | 386.45 | 311.63 |
Capital Expenditures |
(0.05) | (0.29) | (1.06) | (0.80) | (0.57) | (1.35) | (0.36) | (0.81) | (0.36) | (0.09) |
Net Current Asset Value |
35.30 | 230.91 | 411.58 | 347.54 | 376.74 | 267.23 | 98.93 | 42.55 | 18.91 | 23.07 |
EV/EBIT |
2.48 | 0.00 | 0.00 | 0.73 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15 | 12.95 |
Capex to Sales |
0.00 | 0.03 | 0.21 | 0.10 | 0.01 | 0.02 | 0.03 | 0.05 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.41 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.49 | 0.28 | (0.64) | (0.76) | 1.17 | 1.13 | (0.08) | (3.88) | (4.28) | (1.69) |
Cash ROIC |
(8.70%) | (3.50%) | (5.43%) | (9.02%) | (1.86%) | (5.23%) | (10.51%) | (25.39%) | (29.74%) | 5.62% |
Accounts Receivable Turnover |
5.08 | 2.88 | 5.63 | 0.00 | 0.00 | 120.33 | 8.96 | 4.15 | 3.83 | 6.29 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
3.28 | 3.47 | 0.89 | — | — | 0.53 | 1.15 | 4.14 | 23.81 | 37.31 |
Average Payables |
1.90 | 2.30 | 3.88 | 10.84 | 10.23 | 2.98 | 2.26 | 3.74 | 4.35 | 3.94 |
Average Assets |
59.23 | 195.77 | 419.18 | 472.10 | 425.87 | 529.81 | 626.73 | 531.39 | 468.11 | 424.11 |
Average Common Equity |
(36.71) | 134.67 | 396.97 | 445.69 | 400.87 | 376.58 | 309.27 | 175.10 | 79.49 | 54.04 |
Columns are period end dates